|
시장보고서
상품코드
2075820
천식 및 COPD 시장 : 약제 유형별, 질환 유형별, 유통 채널별 및 지역별Asthma And COPD Market, By Drug Type, By Disease Type, By Distribution Channel, and By Region |
||||||
천식 및 COPD 시장은 2026년에 407억 1,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 576억 6,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 5.1%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 407억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 5.10% | 시장 규모 예측(2033년) : | 576억 6,000만 달러 |
천식이란 환자의 기도가 좁아지고, 부어오르며, 과도한 점액이 분비되는 상태를 말합니다. 이로 인해 호흡이 어려워지고, 기침, 숨을 내쉴 때 나는 휘파람 같은 소리(천명), 숨가쁨이 나타날 수 있습니다. 사람에 따라서는 천식이 경미한 불편감에 그치기도 하지만, 다른 사람들에게는 일상생활에 지장을 주는 큰 문제가 되며, 생명을 위협하는 천식 발작을 일으킬 가능성도 있습니다. 천식은 완전히 낫지는 않지만, 증상을 조절하는 것은 가능합니다. 천식은 시간이 지남에 따라 증상이 변하는 경우가 많으므로, 환자가 의사와 협력하여 징후와 증상을 파악하고, 필요에 따라 치료를 조정하는 것이 중요합니다. COPD는 기도가 막혀 천명음이나 호흡 곤란을 일으키는 만성 염증성 폐질환입니다.
시장 역학
신제품 출시가 세계 천식 및 COPD 시장의 성장에 기여하고 있습니다. 예를 들어, 2021년 6월, 연구 개발 중심의 세계 제약 기업인 GLENMARK PHARMACEUTICALS LTD는 만성 폐쇄성 폐질환(COPD) 치료제인 티오트로피움 브로마이드 건식 분말 흡입기(DPI) 'Tiogiva'를 영국에서 출시했습니다. 'Tiogiva'의 유효 성분인 티오트로피움 브로마이드(bromide)는 기관지 확장제로, 기도 근육을 이완시켜 기도를 넓히는 작용이 있습니다. 이러한 기관지 확장 작용을 통해 티오트로피움은 호흡 곤란, 천명음, 기침, 가슴 답답함 등 COPD의 다양한 증상을 완화할 수 있습니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 세계 천식 및 COPD 시장의 주요 기업 프로파일을 소개했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 세계 천식 및 COPD 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 천식 및 COPD 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 천식 및 COPD 시장 : 약제 유형별(2021-2033년)
제5장 세계의 천식 및 COPD 시장 : 질환 유형별(2021-2033년)
제6장 세계의 천식 및 COPD 시장 : 유통 채널별(2021-2033년)
제7장 세계의 천식 및 COPD 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
AJY 26.07.09Asthma And COPD Market is estimated to be valued at USD 40.71 Bn in 2026 and is expected to reach USD 57.66 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 40.71 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.10% | 2033 Value Projection: | USD 57.66 Bn |
Asthma is a condition in which a patient's airways narrow and swell and may produce extra mucus. This can make breathing difficult and trigger coughing, a whistling sound (wheezing) when a patient breathes out and shortness of breath. For some people, asthma is a minor nuisance, for others, it can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack. Asthma cannot be cured, but its symptoms can be controlled. Because asthma often changes over time, it's important that a patient works with doctors to track the signs and symptoms and adjust your treatment as needed. COPD is a chronic inflammatory lung disease, in which airways become blocked, leading to wheezing and shortness of breath.
Market Dynamics
The launch of new products is attributed to the growth of the global asthma and COPD market. For instance, in June 2021, GLENMARK PHARMACEUTICALS LTD, a research-based, global pharmaceutical company, launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva's active ingredient, tiotropium bromide, is a bronchodilator- an agent that relaxes airway muscles so they can widen. Due to its bronchodilator properties, tiotropium can ease several COPD symptoms, including shortness of breath, wheezing, coughing, and chest tightness.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global asthma and COPD market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca, Novartis AG, GSP plc, Merck & Co., Inc., Verona Pharma plc, Regeneron Pharmaceuticals Inc., and Boehringer Ingelheim International GmbH
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding its future product launches, type up-gradation, market expansion, and marketing tactics
- Global asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global asthma and COPD market.
Detailed Segmentation:
- Global Asthma And COPD Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anti-Inflammatories
- Inhaled Corticosteroids
- Leukotriene Modulators
- Others
- Bronchodilators
- Combined Therapies
- Global Asthma And COPD Market, By Disease type (Revenue, USD Bn, 2021 - 2033)
- By Disease Type
- Asthma
- COPD
- Global Asthma And COPD Market, By Dsitribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharemacies
- Online Pharmacies
- Global Asthma And COPD Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AstraZeneca
- Novartis AG
- GSP plc,
- Merck & Co., Inc.
- Verona Pharma plc
- Regeneron Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Asthma And COPD Market, By Drug Type, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anti-Inflammatories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Inhaled Corticosteroids
- Leukotriene Modulators
- Others
- Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
5. Global Asthma And COPD Market, By Disease Type, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- COPD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
6. Global Asthma And COPD Market, By Distribution Channel, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
7. Global Asthma And COPD Market, By Region, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSP plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Verona Pharma plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
